Spotlight on Allergy & Immunology

Credits: 0.75 CME
Clinical Convergence®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients
Jonathan Silverberg, MD, PhD, MPH
Postgraduate Institute for Medicine

Clinical Convergence®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: August 30, 2018
Expires: August 29, 2019
45 minutes to complete

Target Audience

US-based dermatology and allergy/immunology clinicians who manage patients with atopic dermatitis (AD)

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  2. Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Faculty

Jonathan I. Silverberg, MD, PhD, MPH (Chair)
Associate Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL

Jonathan I. Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, Glenmark, Kiniksa, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Realm, Regeneron-Sanofi, and Roivant (Consulting Fees); Regeneron-Sanofi (Speakers’ Bureau); and Galderma, GlaxoSmithKline, and Regeneron-Sanofi (Contracted Research).


Eric L. Simpson, MD, MCR
Professor of Dermatology, Department of Dermatology
Oregon Health & Science University
Portland, OR

Eric L. Simpson, MD, MCR, has affiliations with AbbVie, Eli Lilly, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Regeneron, and Sanofi Genzyme (Consulting Fees); Eli Lilly, Glaxo Smith Kline, LEO Pharma Inc., Novartis, Regeneron Pharmaceuticals, Inc., and Roivant (Contracted Research).

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

YOUR FEEDBACK IS IMPORTANT!
Complete the Evaluation form for this activity and be entered into a drawing for a $100* Amazon Gift card.

*The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. If you would like to contact RMEI, please email contact@RMEI.com.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Allergy & Immunology Presentations

0.75 CME
Postgraduate Institute for Medicine
Clinical Conversations: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Clinical Conversations: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: September 25, 2018
Expires: September 24, 2019
45 minutes to complete

Target Audience

US-based dermatology and allergy/immunology clinicians who manage patients with atopic dermatitis (AD)

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  2. Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Faculty

Jonathan I. Silverberg, MD, PhD, MPH (Chair)
Associate Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL

Jonathan I. Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, Glenmark, Kiniksa, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Realm, Regeneron-Sanofi, and Roivant (Consulting Fees); Regeneron-Sanofi (Speaker’s Bureau); and Galderma, GlaxoSmithKline, and Regeneron-Sanofi (Contracted Research).


Eric L. Simpson, MD, MCR
Professor of Dermatology, Department of Dermatology
Oregon Health & Science University
Portland, OR

Eric L. Simpson, MD, MCR, has affiliations with AbbVie, Eli Lilly, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Regeneron, and Sanofi Genzyme (Consulting Fees); Eli Lilly, Glaxo Smith Kline, LEO Pharma Inc., Novartis, Regeneron Pharmaceuticals, Inc., and Roivant (Contracted Research).

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

YOUR FEEDBACK IS IMPORTANT!
Complete the Evaluation form for this activity and be entered into a drawing for a $100* Amazon Gift card.

*The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. If you would like to contact RMEI, please email contact@RMEI.com.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

0.75 CME
Postgraduate Institute for Medicine
Clinical Convergence®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Clinical Convergence®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: August 30, 2018
Expires: August 29, 2019
45 minutes to complete

Target Audience

US-based dermatology and allergy/immunology clinicians who manage patients with atopic dermatitis (AD)

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  2. Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Faculty

Jonathan I. Silverberg, MD, PhD, MPH (Chair)
Associate Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL

Jonathan I. Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, Glenmark, Kiniksa, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Realm, Regeneron-Sanofi, and Roivant (Consulting Fees); Regeneron-Sanofi (Speakers’ Bureau); and Galderma, GlaxoSmithKline, and Regeneron-Sanofi (Contracted Research).


Eric L. Simpson, MD, MCR
Professor of Dermatology, Department of Dermatology
Oregon Health & Science University
Portland, OR

Eric L. Simpson, MD, MCR, has affiliations with AbbVie, Eli Lilly, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Regeneron, and Sanofi Genzyme (Consulting Fees); Eli Lilly, Glaxo Smith Kline, LEO Pharma Inc., Novartis, Regeneron Pharmaceuticals, Inc., and Roivant (Contracted Research).

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

YOUR FEEDBACK IS IMPORTANT!
Complete the Evaluation form for this activity and be entered into a drawing for a $100* Amazon Gift card.

*The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. If you would like to contact RMEI, please email contact@RMEI.com.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

1.00 CME
Postgraduate Institute for Medicine
Clinical Reflections®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Clinical Reflections®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: June 28, 2018
Expires: June 27, 2019
1 hour

Target Audience

US-based dermatology and allergy/immunology clinicians who manage patients with atopic dermatitis (AD)

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Apply current principles of pathophysiology of atopic dermatitis (AD) and the concept of atopic march to therapeutic approaches to disease management
  2. Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  3. Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD
  4. Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Faculty

Jonathan I. Silverberg, MD, PhD, MPH (Chair)
Associate Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL

Jonathan I. Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, Glenmark, Kiniksa, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Realm, Regeneron-Sanofi, and Roivant (Consulting Fees); Regeneron-Sanofi (Speakers’ Bureau); and Galderma, GlaxoSmithKline, and Regeneron-Sanofi (Contracted Research).


Emma Guttman, MD, PhD
Professor of Dermatology, Sol and Clara Kest
Icahn School of Medicine at Mount Sinai
New York, NY

Emma Guttman, MD, PhD, has affiliations with AbbVie, Allergan, Almirall, Amgen, Anacor, AnaptyBio, Asana Biosciences, BMS, Celgene, Curadim, Dermira, Drais, Eli Lilly, Escalier, Galderma, Glenmark, Kiowa Kirin, Kymab Limited, Lead Pharma, LEO Pharma Inc., Medimmune, Novartis, Pfizer, Regeneron, Sanofi, Sienna, Stiefel/GlaxoSmithKline, Theravance, and Vitae (Consultant).


Eric Simpson, MD, MCR
Professor of Dermatology, Department of Dermatology
Oregon Health & Science University
Portland, OR

Eric Simpson, MD, MCR, has affiliations with AbbVie, Eli Lilly, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Regeneron, and Sanofi Genzyme (Consulting Fees); Eli Lilly, Glaxo Smith Kline, LEO Pharma Inc., Novartis, Regeneron Pharmaceuticals, Inc., and Roivant (Contracted Research).

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.75 CME
Integrity Continuing Education, Inc.
Optimizing the Care of Patients with Severe Asthma through Personalized Disease Management

Optimizing the Care of Patients with Severe Asthma through Personalized Disease Management

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: June 25, 2018
Expires: June 25, 2019
45 minutes to complete

Provided By


Integrity Continuing Education, Inc.

Target Audience

This educational initiative has been designed for allergists, pulmonologists, and internal medicine physicians involved in the care of patients with severe asthma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify known phenotypes and endotypes that can inform the development of personalized treatment plans for patients with severe asthma
  • Describe clinical trial data on the efficacy and safety of new and emerging therapies for the treatment of severe asthma
  • Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma

Activity Description

Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this educational activity will provide clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.

Faculty

J. Mark FitzGerald, MD
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia


Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, Colorado


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

J. Mark FitzGerald, MD
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Merck, Novartis Pharmaceuticals Corporation, TEVA
Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Merck, Novartis Pharmaceuticals Corporation, TEVA
Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi

Michael E. Wechsler, MD, MMSc
Consulting Fees: Amgen, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi/Regeneron, TEVA
Contracted Research: AstraZeneca Pharmaceuticals LP, Sanofi/Regeneron, TEVA

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 25, 2018 through June 25, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 80% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and AstraZeneca Pharmaceuticals LP do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

1.00 CME
University of California, San Diego School of Medicine
Issues and Updates in Hereditary Angioedema

Issues and Updates in Hereditary Angioedema

Start

Jointly Provided By

University of California, San Diego School of Medicine and RMEI Medical Education, LLC.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: December 27, 2017
Expires: December 27, 2018
1.0 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of allergy/immunology physicians, allergy/immunology NPs and PAs, dermatology physicians, dermatology NPs and PAs.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Recognize the possibility of hereditary angioedema (HAE) in patients who present with angioedema and integrate a diagnostic workup for angioedema that includes analysis for the various types of HAE (Type I, Type II, and normal C1-INH)
  2. Incorporate current, novel, and emerging treatments for HAE based on an understanding of their efficacy, safety, and guidance for use

Activity Description

This interactive multi-challenge activity addresses issues and updates in HAE. Based on the proceedings from a live continuing medical education series, it contains slides, expert audio, and commentary on some of the most current and important topics in HAE. Patient case challenges allow you to test your knowledge and skill in diagnosing and treating this important disease. Commentary from faculty experts will increase your understanding of the newest developments in HAE.

Statement of Educational Need

The treatment of hereditary angioedema (HAE) is rapidly evolving. After many years of limited treatment options, several effective medications for HAE have been introduced into clinical practice over the past 8 years. Now, a second wave of novel therapies are poised to reach the clinic. While the impact of these treatments is not yet known, it is likely the HAE treatment paradigm will shift yet again given the broadening therapeutic options available to physicians and patients.

Faculty

Marc A. Riedl, MD, MS
Professor of Medicine 
Clinical Director, US HAEA Angioedema Center 
Division of Rheumatology, Allergy and Immunology 
University of California, San Diego 
San Diego, CA


Michael E. Manning, MD, FAAAAI, FACAAI
President/Medical Director 
Medical Research of Arizona 
Allergy, Asthma & Immunology Associates, Ltd. 
Scottsdale, AZ


Daniel F. Soteres, MD, MPH
Physician Partner
Asthma & Allergy Associates and Research Center
Colorado Springs, CO


Disclosure of Conflicts of Interest

It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity, and scientific rigor. All persons involved in the selection, development, and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms: 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Marc A. Riedl, MD, MS, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Ionis, Pharming, Shire (Research); Adverum, Alnylam, BioCryst, CSL Behring, KalVista, Pharming, Shire (Consulting Fees)
  • Michael E. Manning, MD, FAAAAI, FACAAI, has affiliations with CSL Behring, Dyax, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Dyax, Pharming, Shire (Research); CSL Behring, Pharming, Shire (Advisory Board); CSL Behring (Consulting Fees)
  • Daniel F. Soteres, MD, MPH, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); CSL Behring, Shire (Research); CSL Behring, Shire (Advisory Board); CSL Behring, Pharming, Shire (Consulting Fees)

The CME staff, meeting planners, and CME committee reviewers do not have any relevant financial relationships to disclose.

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, San Diego School of Medicine and RMEI Medical Education, LLC. The University of California, San Diego School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The University of California, San Diego School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cultural Competency
This activity is in compliance with California Assembly Bill 1195 which requires CME courses with patient care components to include curriculum in the subjects of cultural and linguistic competencies. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables healthcare professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient's primary language. Cultural and Linguistic Competency was incorporated into the planning of this activity. Additional resources on cultural and linguistic competency and information about AB1195 can be found on the UC San Diego CME website at http://cme.ucsd.edu.

How to Receive Credit

The estimated time to complete this activity is 1 hour. To obtain credit, participants should view the presentation, answer the multiple-choice post-test questions, and complete the evaluation form online to receive a certificate.

Physicians/DOs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

The activity is supported in part by educational grants from CSL Behring, Pharming Healthcare, Inc., and Shire.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.50 CME
Postgraduate Institute for Medicine
First Know Thyself: Improving Patient Outcomes in Moderate-to-Severe and Difficult to Treat Pediatric Asthma

First Know Thyself: Improving Patient Outcomes in Moderate-to-Severe and Difficult to Treat Pediatric Asthma

Start

Jointly Provided By

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: December 12, 2017
Expires: December 12, 2018
30 minutes to complete

Target Audience

Allergy/Immunology and pulmonology clinicians who manage pediatric patients with asthma.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Optimally utilize recommended therapy algorithms and therapies for asthma in children 6 to 11 years of age based on new data and guidelines
  2. Better define optimal asthma control in childhood in order to implement asthma control
  3. Implement newer and more effective treatment for children with resistant or moderate-to-severe and severe asthma based on efficacy and safety data and different asthma endotypes
  4. Employ a strong patient-provider collaborative approach to managing pediatric patients with asthma that includes patient and caregiver education, engagement, and shared decision making

Faculty

Bradley E. Chipps, MD
Medical Director, Respiratory Therapy and the Cystic Fibrosis Center
Sutter Medical Center
Capital Allergy and Respiratory Disease Center
Sacramento, CA


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Bradley E. Chipps, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Novartis, and TEVA (Consulting Fees).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Leslie Sharp has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
Planners and Managers
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an educational grant from Genentech.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.